Articles

Symyx and Certara: When more money isn’t enough

Symyx board rejects larger offer from Certara for more ownership with Accelrys
Written byJeffrey Bouley
| 2 min read

SANTA CLARA, Calif.—Twice in one week—on June 21 and then on June 25—the board of directors of Symyx Technologies has rejected a bid from Certara to acquire the firm for $5.75 per share, or about $200 million. According to Symyx, the offer does not constitute a superior offer to Accelrys' rival bid to acquire the company, even though San Diego-based Accelrys is only bidding $5 per share.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.